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INTRODUCTION
Patients with ulcerative colitis may need surgery for their 
disease and proctocolectomy with ileal-pouch anal anasto-
mosis (IPAA) is the surgical procedure of  choice for the 
management of  these patients[1,2]. Most patients undergo-
ing IPAA for severe colitis or chronic continuous disease 
achieve good functional results, but some patients develop 
pouchitis, a non-specific idiopathic inflammation of  the 
ileal reservoir. Frequency rates of  pouchitis are highly vari-
able, ranging 10-59% depending on the length of  follow-
up and the diagnostic criteria used[3]. Though the origin of  
pouchitis remains unknown, genetic and immunological 
factors are likely to be involved in addition to ileal mucosa 
that needs to adapt to its new role as a reservoir[4]. This is 
illustrated by the fact that pouchitis occurs almost exclu-
sively in patients with IPAA for ulcerative colitis and not 
in patients with IPAA for familial adenomatous polyposis, 
a hereditary non-infl ammatory disease of  the colon with 
high risk of  developing colon cancer. An important role 
of  luminal bacteria in the development of  pouchitis is un-
derscored by various reports on bacterial overgrowth and 
dysbiosis in pouchitis[5] and is further confi rmed by the ef-
fi cacy of  antibiotic and probiotic therapy[6,7].
    Pattern recognition receptors (PRRs), including Toll-like 
receptors (TLRs), are essential components of  the innate 
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Abstract    
AIM: To investigate the single nucleotide polymorphisms 
(SNPs) in genes involved in bacterial recognition and the 
susceptibility to pouchitis or pouchitis severity. 
METHODS: Analyses of CD14 -260C>T, CARD15/
NOD2 3020insC, Toll-like receptor (TLR )4 +896A>G, 
TLR9 -1237T>C, TLR9 +2848G>A, and IRAKM  + 
22148G>A SNPs were performed in 157 ileal-pouch 
anal anastomosis (IPAA) patients (79 patients who did 
not develop pouchitis, 43 infrequent pouchitis patients, 
35 chronic relapsing pouchitis patients) and 224 Italian 
Caucasian healthy controls.  
RESULTS: No significant differences were found in 
SNP frequencies between controls and IPAA patients. 
However, a signifi cant difference in carriership frequency 
of the TLR9 -1237C allele was found between the 
infrequent pouchitis and chronic relapsing pouchitis 
groups [P = 0.028, odd’s ratio (OR) = 3.2, 95%CI = 1.2-8.6]. 
This allele uniquely represented a 4-locus TLR9 haplotype 
comprising both studied TLR9 SNPs in Caucasians. 
Carrier trait analysis revealed an enhanced combined 
carriership of the alleles TLR9 -1237C and CD14 -260T 
in the chronic relapsing pouchitis and infrequent pouchitis 
group (P = 0.018, OR = 4.1, 95%CI = 1.4 -12.3).
Combined carriership of TLR9  -1237C and CD14  -260T alleles 
enhances the risk of developing chronic relapsing pouchitis 
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CONCLUSION: There is no evidence that the SNPs 
predispose to the need for IPAA surgery. The signifi cant 
increase of the combined carriership of the CD14 
-260T and TLR9 -1237C alleles in the chronic relapsing 
pouchitis group suggests that these markers identify 
a subgroup of IPAA patients with a risk of developing 
chronic or refractory pouchitis. 
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immune system as recognition of  microbial products oc-
curs via PRRs that are expressed by innate effector cells. 
Microbial recognition results in a rapid and effi cient im-
mune response against invading microorganisms[8].
    Given the role of  luminal bacteria in driving the infl am-
matory response in pouchitis, identifi cation and functional 
characterization of  polymorphisms in innate immunity 
genes may provide insight in a possible genetically deter-
mined susceptibility to pouchitis and/or chronic relapsing 
pouchitis[9].
    CD14 is part of  the endotoxin/lipopolysaccharide 
(LPS) receptor complex[8] and is important in conjunc-
tion with TLR4 and with TLR2[10] in the recognition of  
LPS, a membrane glycolipid on Gram-negative bacteria. 
CD14 may also recognize cell membrane components of  
Gram-positive mycobacteria and viruses[11-15]. CD14 ex-
ists in a membrane form on monocytes and neutrophils 
and in a soluble form in serum[16-18]. The SNP at position 
-260C>T (also known as CD14-159C>T) in the promoter 
region of  the CD14 gene (located on chromosome 5q31) 
is associated with enhanced transcriptional activity[19] 
and signifi cantly higher CD14 serum levels[20]. Increased 
expression of  CD14 in macrophages has been found in 
infl ammatory bowel disease (IBD)[21]. An association of  
the CD14-260C>T gene polymorphism with IBD[22.23] 
and atherosclerosis[24] has been described. Genetically de-
termined variation in CD14 serum levels may have func-
tional consequences given the ability of  soluble CD14 to 
confer pathogen responsiveness to cells such as intestinal, 
epithelial and endothelial cells that do not express CD14 
on their membranes[25].
    The TLR4 gene is located on chromosome 9q32-q33. 
The TLR4+896A>G SNP affects the leucine-rich repeat 
domain of  TLR4 and is associated with hyporesponsive-
ness to LPS[26] with increased susceptibility to severe bac-
terial infections and IBD[27] and may predispose to septic 
shock with Gram-negative microorganisms[28,29].
    TLR9 is required for the recognition of  CpG motifs, 
short sequences of  unmethylated DNA predominantly 
present in bacterial DNA. CpG motifs have immunos-
timulatory activity by inducing dendritic cell maturation, 
B-cell proliferation and production of  cytokines, including 
interleukin-6 (IL-6) and interleukin-12 (IL-12)[30,31]. TLR9 
signaling has been shown to mediate the resolution of  
intestinal infl ammation in experimental colitis[32], suggest-
ing that the release of  bacterial DNA from the microfl ora 
might favor immune homeostasis. The promoter TLR9 
-1237T>C SNP located on chromosome 3p21.3 is asso-
ciated with susceptibility to asthma in European Ameri-
cans, but not in Hispanic or African Americans[33] and the 
marker D3S1076 in this region shows association with 
IBD in a classical TDT test[42]. Török and colleagues[34] 
studied the TLR9 -1237T>C and TLR9+2848 G>A 
SNPs in German patients with Crohn’s disease, ulcerative 
colitis and healthy blood controls and found that the allele 
TLR9 -1237C carrier status is associated with Crohn’s disease 
compared to controls. TLR9 +2848 G>A allele frequen-
cies are not different between the study groups. 
    CARD15/NOD2 is a cytoplasmatic bacterial PRR 
expressed in monocytes and intestinal epithelial cells and 
mediates response against muramyl dipeptide derived from 
peptidoglycan[35,36]. The CARD15/NOD2 gene is located 
on chromosome 16q12. Three major polymorphisms in 
this gene (R702W, G908R, and L1007 frameshift muta-
tion) are associated with susceptibility to Crohn’s disease, 
possibly as a result of  a defective response against mu-
ramyl dipeptide derived from peptidoglycan[37]. Recently, 
an increased frequency of  the L1007 frameshift mutation 
has been observed in Italian patients with ulcerative colitis 
when compared to controls[38].
    The intracellular domains of  TLRs are homologous 
to the interleukin-1 receptor (IL-1R) type I intracellular 
domain and use a common pathway of  intracellular signal-
ing with shared components including the protein kinase 
IL-1R-associated kinase1 (IRAK1) and IRAK-M, as a 
negative regulator of  TLR signaling. Cytokine production 
increases in IRAK-M-/- macrophages after TLR/IL-1 
stimulation and bacterial challenge, while endotoxin tol-
erance reduces in these cells. Furthermore, IRAK-M-/- 
mice have increased infl ammatory responses to bacterial 
infection and develop intestinal inflammation. These 
data suggest that IRAK-M has a regulatory function in 
TLR/IL-1R signaling and innate immune homeostasis[39]. 
The IRAKM (or IRAK3) gene is located at chromosome 
12q14.2 within the IBD2 region associated with ulcerative 
colitis[40,41]. Genetic variation in the IRAKM gene may be 
involved in the development of  chronic intestinal infl am-
mation. For this reason, we chose to analyze a non-synon-
ymous SNP in exon 5 resulting in an Ile/Val substitution.
    A candidate gene approach, based on the determination 
of  frequencies of  functional SNPs, can be used to inves-
tigate the relevance of  genes to the disease susceptibility 
and severity. Carrier trait analysis investigates combina-
tions of  SNPs and allows studying the implication of  
different SNPs in disease susceptibility and severity as a 
result of  their synergistic action.
    The aim of  this study was whether SNPs in innate 
immunity genes could contribute to the susceptibility to 
pouchitis and/or severity of  pouchitis. We chose candi-
date genes of  CD14, TLR4, TLR9, NOD2/CARD15, and 
IRAKM for their involvement in bacterial recognition and 
intracellular signaling pathways.
MATERIALS AND METHODS
Patients 
One hundred and fi fty-seven unrelated patients with IPAA 
for ulcerative colitis and 224 healthy blood donors were 
studied. All individuals were Italian Caucasians. Consent 
was obtained and the local ethics committee approved 
the protocol. Their demographic and clinical information 
is described in Table 1. IPAA patients were subdivided 
into three test groups according to the pouchitis pattern. 
One group consisted of  IPAA patients who had never 
developed pouchitis, another group consisted of  IPAA 
patients who had up to two episodes of  pouchitis during 
IPAA (infrequent pouchitis) and third group consisted of  
IPAA patients who developed three or more episodes of  
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pouchitis (chronic relapsing pouchitis). 
DNA isolation 
Venous blood (5-10 mL) was drawn and genomic DNA 
was isolated using standard protocols. Polymorphisms of  
the CD14, TLR4, TLR9, CARD15/NOD2, and IRAKM 
genes in these three groups were analyzed. Genomic 
DNA (5-100 ng) was used for each genotyping.
Analysis of gene polymorphisms
Polymerase chain reaction (PCR) for RFLP analyses was 
performed on a thermal cycler GeneAmp 9700 (Perkin-
Elmer Cetus, Norwalk, CT, USA). Digested fragments 
were analyzed on a 4% agarose gel except for the IRAKM 
SNP analyzed on a 2% agarose gel and visualized with 
an UV-illuminator after ethidium bromide staining. SNPs 
were analyzed with the TaqMan assay (Applied Biosystems, 
Foster City, CA, USA). MGB TaqMan probes and primer 
pairs were designed with Primer Express software (version 
2.0). TaqMan thermocycling consisted of  an initial step 
at 50 ℃ for 2 min and denaturation at 95 ℃ for 10 min 
followed by 40 cycles of  denaturation at 95 ℃ for 15 s and 
annealing/extension at 60 ℃ for 1 min. We used the ABI 
Prism 7000 sequence detector (Applied Biosystems) for 
data acquisition.
Genotyping 
CD14-260C>T genotyping (NCBI SNP CLUSTER ID: 
rs2569190) was performed by PCR. Primers used were: 
forward primer 5’-TCA CCT CCC CAC CTC TCT T-3’ 
and reverse primer 5’-CCT GCA GAA TCC TTC CTG 
TT-3’. The PCR conditions were initial denaturation at 
95 ℃ for 5 min, followed by 35 cycles of  denaturation at 
95 ℃ for 30 s, annealing at 59 ℃ for 30 s, extension at 
72 ℃ for 1 min and a fi nal extension at 72 ℃ for 5 min 
followed by cooling to 4 ℃. The 107-bp amplicons were 
digested overnight with HaeIII (New England Biolabs, 
UK). Digestion resulted in two fragments of  83 and 24 bp 
(C allele) or 107 bp (T allele), respectively.
    Genotyping of  the TLR4+896 A>G SNP (NCBI SNP 
CLUSTER ID: rs4986790) was performed with forward 
primer 5’-TTT ACC CTT TCA ATA GTC ACA CTC A-3’ 
and reverse primer 5’-AGC ATA CTT AGA CTA CTA CCT 
CCA TG-3’. PCR conditions were: initial denaturation at 
94 ℃ for 5 min followed by 35 cycles of  denaturation 
at 94 ℃ for 30 s, annealing at 55 ℃ for 30 s, extension 
at 72 ℃ for 30 s and a fi nal extension at 72 ℃ for 5 min 
followed by cooling to 4 ℃. The 102-bp amplicons were 
digested overnight with NcoI (New England Biolabs, UK). 
Digestion resulted in two fragments of  80 and 22 bp (G 
allele) or 102 bp (A allele), respectively.
    CARD15/NOD2 3020InsC (CARD15 L1007fs) (NCBI SNP 
CLUSTER ID: rs2066847) genotyping was performed with 
forward primer 5’-GGC AGA AGC CCT CCT GCA GGG 
CC-3’ and reverse primer 5’-CCT CAA AAT TCT GCC ATT 
CC-3’. PCR conditions were: initial denaturation at 94 ℃ 
for 5 min followed by 35 cycles of  denaturation at 94 ℃ 
for 30 s, annealing at 59 ℃ for 30 s, extension at 72 ℃ 
for 45 s and a fi nal extension at 72 ℃ for 5 min followed 
by cooling to 4 ℃. The 150-bp amplicons were digested 
overnight with ApaI. Digestion resulted in a fragment of  
150 bp (no insertion) or 128 bp and 22 bp (insertion C), 
respectively.
    TLR9-1237T>C (NCBI SNP CLUSTER ID: rs5743836) 
genotyping was performed with TaqMan method. Primers used 
were: forward primer 5’-GGC CTT GGG ATG TGC TGT T-3’ 
and reverse primer 5’-GGT GAC ATG GGA GCA GAG 
ACA-3’. Dual-labeled fl uorogenic hybridization MGB-probes 
used were: CTGCCTGAAAACT 5’ Fluor Label (FAM, 
6-carboxyfluorescein) and CTGGAAACTCCCC 5’ Fluor 
Label (VIC).
    TLR9+2848G>A genotyping (NCBI SNP CLUSTER 
ID: rs352140) was performed with TaqMan method. 
Primers used were: forward primer 5’-CCG GTC TGC 
AGG TGC TAG AC-3’ and reverse primer 5’-CCA 
AAG GGC TGG CTG TTG TA-3’ . Dual- labeled 
f luorogenic hybridization MGB probes used were: 
AGCTACCGCGACTGG 5’ Fluor Label (FAM) and 
AGCTACCACGACTGGA 5’ Fluor Label (VIC).
    Genotyping of the IRAKM+22148G>A exon 5 SNP (NCBI 
SNP CLUSTER ID: rs1152888) was performed by PCR with 
forward primer 5´-AGT GGA AC T GAT GTC CTG TGA 
CAG-3´  and reverse primer 5´-GCA ACA CAT TGA CCT AAT 
GAC CAG-3 .´
    The PCR conditions were: initial denaturation at 95 ℃ 
for 5 min, followed by 35 cycles of denaturation at 95 ℃ for 50 
s, at 60 ℃ for 50 s, at 72 ℃ for 150 s and a fi nal extension 
at 72 ℃ for 5 min followed by cooling to 4 ℃. Digestion 
overnight with RsaI (Invitrogen Life Technologies) of  the 
505-bp amplicons resulted in two fragments of  188+317 
bp (allele G) or 505 bp (allele A).
 
Statistical analysis 
Hardy-Weinberg equilibrium was determined in healthy 
controls to assess the Mendelian inheritance. Comparisons 
of  the genotypes between control and different groups 
of  IPAA patients were performed by Fisher’s exact or χ2 
two-tailed tests where appropriate. Carrier trait analysis 
was performed to determine whether combinations of  
SNPs were acting synergistically on the risk of  developing 
pouchitis or of  predisposing to chronic relapsing 
pouchitis. Adjusted odd’s ratio (OR) and 95% confi dence 
intervals (95%CI) were calculated. P<0.05 was considered 
statistically signifi cant.
RESULTS
Characteristics of patients and control groups
The demographic features of  IPAA patients and healthy 
Table 1 Demographic features of IPAA patients and healthy controls
IPAA patients Healthy controls
Total number (n) 157 224
Gender M/F 88/69 118/106
Mean age in yr (SD) 42.9 (11.8) 45.8 (12.8)
Range 17-73 21-77
Median 41 45.5
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controls are shown in Table 1. No statistical differences 
were found in the variables including gender and age 
between the IPAA group and healthy controls. 
    The clinical characteristics of  patients with IPAA for 
ulcerative colitis were summarized. Information on the 
pattern of  pouchitis within the group of  IPAA patients for 
ulcerative colitis (patients who did not develop a pouchitis, 
patients who had infrequent pouchitis and patients who 
suffered from chronic relapsing pouchitis, respectively) is 
shown in Table 2. No statistically significant differences 
were found in gender and age between controls and IPAA 
patients as well as in the duration of  pouch and the fi rst 
episode of  pouchitis after IPAA, respectively and among 
IPAA groups and between infrequent pouchitis and 
chronic relapsing pouchitis groups.
 Genotyping 
The genotype frequencies in the control group were in 
Hardy-Weinberg equilibrium for the CD14, TLR4, TLR9, 
CARD15/NOD2, and IRAKM gene polymorphisms. 
The genotype frequencies of  these polymorphisms 
are described in Table 3. No significant differences in 
allele-, genotype- or carrier frequencies of  the gene 
polymorphisms were found between the healthy controls 
and IPAA patients.
    No signifi cant differences in allele-, genotype- or carrier 
frequencies of  the gene polymorphisms were found 
between the three subgroups of  IPAA patients except that 
the carriership of  allele TLR9 -1237 C was more frequent 
in patients with chronic relapsing pouchitis (45.7%) as 
compared to those with infrequent pouchitis (20.9%) (P =0.028, 
OR = 3.2, 95%CI = 1.2-8.6). When the combined groups 
of  infrequent pouchitis and chronic relapsing pouchitis 
(i.e. total pouchitis group) were compared to the patients 
without pouchitis, carriership of  this allele was not 
signifi cantly different (P = 0.87, OR = 1.1, 95%CI = 0.6-2.1).
TLR9 haplotype 
The two analyzed TLR9 SNPs were chosen based on the 
study of  Lazarus et al.[33] in which a set of  four frequent 
TLR9 SNPs designated as TLR9 -1486, TLR9 -1237, TLR9 
+1174, and TLR9 +2848, were described. Genotyping of  
both TLR9 -1237 and TLR9 +2848 could distinguish all 
four-locus haplotypes commonly present in the European 
American population. We therefore calculated the 
haplotypic genotypes in Italian Caucasians (Table 4). The 
haplotype frequencies in the healthy controls were identical 
to the European-Americans as reported by Lazarus et al.[33]. 
Table 2 Clinical data obtained from IPAA patients
IPAA patients Mean (SD) Median Range
Age (yr) at diagnosis of ulcerative colitis 29.7 (11.7) 27 8-61
Time (yr) from diagnosis of ulcerative colitis to IPAA surgery 6.3 (5.5)   5 0-34
Time from IPAA surgery to fi rst episode of pouchitis
Total pouchitis group (n = 78) 2.8 (3.1)   2 0-12
Infrequent pouchitis (≤2 episodes, n = 43) 3.7 (3.3)   3 0-12
Chronic relapsing pouchitis (≥3 episodes, n = 35) 2 (2.6)   1 0-12
Pattern of pouchitis
Duration of pouch (yr)    
No episodes of pouchitis (n = 79) 6.3 (4.1)   5 0-14
Infrequent pouchitis (≤2 episodes, n = 43) 7.6 (3.8)   7 1-16
Chronic relapsing pouchitis (≥3 episodes, n = 35) 7.9 (3.6)   7 2–14
Polymorphisms Genotype Controls No pouchitis Infrequent pouchitis Chronic relapsing pouchitis
n = 224 (%) n = 79 (%) n = 43 (%) n = 35 (%)
CD14 –260 C>T CC   55 (24.6) 24 (30.4) 11 (25.6)   7 (20)
CT 102 (45.5) 34 (43) 21 (48.8) 22 (62.9)
TT   67 (29.9) 21 (26.6) 11 (25.6)   6 (17.1)
CARD15 3020InsC WT/WT 218 (97.3) 77 (97.5) 43 (100) 34 (97.1)
WT/InsC     6 (2.7)   2 (2.5)   0 (0)   1 (2.9)
InsC/InsC     0 (0)   0 (0)   0 (0)   0 (0)
TLR4 +896 A>G AA 208 (92.9) 73 (92.4) 38 (88.4) 33 (94.3)
AG   16 (7.1)   5 (6.3)   5 (11.6)   2 (5.7)
GG     0 (0)   1 (1.3)   0 (0)   0 (0)
TLR9 –1237 T>C TT 158 (70.5) 52 (65.8) 34 (79.1) 19 (54.3)
TC   60 (26.8) 24 (30.4)   9 (20.9) 14 (40)
CC     6 (2.7)   3 (3.8)   0 (0)   2 (5.7)
TLR9 +2848 G>A GG   40 (17.9) 20 (25.3)   9 (20.9)   6 (17.1)
GA 104 (46.4) 38 (48.1) 22 (51.2) 16 (45.7)
AA   80 (35.7) 21 (26.6) 12 (27.9) 13 (37.2)
IRAKM +22148G>A GG 181 (80.8) 64 (81) 33 (76.7) 28 (80)
GA   42 (18.8) 14 (17.7)   7 (16.3)   7 (20)
AA     1 (0.4)   1 (1.3)   3 (7)   0 (0)
Table 3 Genotypes of the CD14, CARD15, TLR4, TLR9, and IRAKM gene polymorphisms in subgroups of patients with IPAA and controls
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Haplotype III was more frequent in chronic relapsing 
pouchitis as compared to infrequent pouchitis (P = 0.018; 
OR = 3.0, 95%CI = 1.2-7.1). This haplotype, however, 
did not show nucleotides uniquely present (tag SNPs) on 
position -1486 (allele T present in haplotypes I and III) or 
on position +1174 (allele G present in haplotypes II and 
III), indicating that allele TLR9-1237C could provide the 
strongest association.
Carrier trait analysis 
To investigate if  SNPs in different genes could act 
synergistically on disease susceptibility and/or severity, 
carrier trait analysis with the associated TLR9 allele was 
performed. Simultaneous carriership of  alleles TLR9 
-1237C and CD14 -260T was more frequent in patients 
with chronic relapsing pouchitis as compared to those 
with infrequent pouchitis (P = 0.018, OR = 4.1, 95%CI = 
1.4-12.3), which was more signifi cant as compared to the 
analysis of  allele TLR9 -1237C alone (P = 0.028, OR = 3.2, 
95%CI = 1.2-8.6). No other signifi cant carrier traits were 
observed.
DISCUSSION
There is convincing evidence that enteric bacteria play a 
role in driving the infl ammatory response in IBD and that 
genetic factors contribute not only to the pathogenesis but 
also to the course and extent of  these disorders. Given 
these processes, we investigated whether polymorphisms 
in the following genes encoding for proteins involved in 
innate immunity, TLR4 +896 A>G, TLR9 +2848 G>A, 
TLR9 -1237T>C, CD14 -260C>T, CARD15/NOD2 
3020insC, and IRAKM +22148 G>A, were associated 
with the development of  pouchitis, disease frequency or 
severity. 
    Analysis of  the three subgroups of  IPAA patients (i.e. 
patients who never developed pouchitis, patients with 
infrequent pouchitis and patients with a chronic refractory 
form of  pouchitis) revealed a positive association of  
allele TLR9 -1237C with the risk of  developing chronic 
refractory pouchitis, once these patients developed 
pouchitis. Haplotype analysis showed that out of  the 
four SNPs defining TLR9 haplotypes, this allele was 
uniquely responsible for this finding. Subsequently, we 
investigated whether interactions of  allele TLR9 -1237C 
with SNPs in the other candidate genes might strengthen 
this association. Carrier trait analysis revealed that an even 
stronger association was apparent with the combination of  
alleles TLR9 -1237C and CD14 -260T. These data suggest 
that this combination of  alleles might be a valuable genetic 
marker to identify a clinical subgroup of  IPAA patients 
with an enhanced risk of  developing chronic pouchitis, 
compared to alleles of  the SNPs TLR4 +896 A>G, TLR9 
+2848 G>A, CARD15/NOD2 3020insC, and IRAKM 
+22148 G>A. 
    It cannot be excluded that the group of  patients who 
did not develop pouchitis consisted of  a mixture of  
patients who never developed pouchitis on the one hand 
and patients who proceeded to the infrequent or chronic 
relapsing pouchitis group on the other hand. This could 
explain why we did not detect an association of  allele 
TLR9 -1237C between the no-pouchitis and the chronic 
relapsing pouchitis groups. It should be noted that no 
signifi cant differences were found in the mean duration of  
IPAA between the three groups.
    At present it is unknown as to what effect of  the 
TLR9-1237 T>C SNP exerts on the expression of  TLR9 
given its location in the far promoter region where no 
DNA-binding site for known transcription factors is 
apparent. The association observed might therefore result 
from linkage disequilibrium with another polymorphism(s) 
in a nearby gene.
    The mechanism underlying increased risk of  developing 
chronic relapsing pouchitis by a combined carriership 
of  alleles TLR9 -1237C and CD14 -260T might be 
a dysfunction in bacterial recognition or a lack of  an 
adequate immune response to bacterial challenge. This 
could start at the level of  the plasmacytoid dendritic cells, 
which play a central role in bacterial recognition, selectively 
express TLR9 and have soluble CD14 facilitating reactivity 
to a broad array of  bacterial components[43] or at the level 
of  the intestinal epithelium. Soluble CD14 might confer 
epithelial cell responsiveness[25].
    The regulatory role of  dendritic cells is of  particular 
impor tance in the in te s t ine where the mucosa l 
immune system is closely associated with the external 
environment[44]. Dendritic cells sample bacterial products 
either indirectly via M cells or directly by reaching between 
epithelial cells into the gut lumen[45]. In this perspective, it is 
noteworthy to mention a recent article that reported a lack 
of  immature blood dendritic cells, which possibly migrate 
to the gut in IBD patients with active disease[46].
    Recently, carriership of  the TLR9 -1237C allele has 
been associated with Crohn’s disease[34]. Ileal involvement 
is present in about 60% of  patients with Crohn’s disease. 
Since the pouch is an ileal reservoir that is more vulnerable 
to the continuous contact with high bacterial titers, it could 
Table 4 Frequencies of TLR9 haplotypes formed by -1237 T>C and +2848 G>A SNPs
TLR9 -1237  +2848 Haplotype Controls No pouchitis Infrequent pouchitis Chronic relapsing pouchitis
2n = 448 2n = 158 2n = 86 2n = 70
T G I 181 (40) 51 (32) 40 (47) 28 (40)
T A II 195 (44) 77 (49) 37 (43) 24 (34)
C A III   69 (15) 29 (18)   9 (10)1 18 (26)1
C G IV     3 (1)   1 (1)    0   0
1P = 0.018, OR = 3.0, 95%CI = 1.2-7.1.
7328    ISSN 1007-9327    CN 14-1219/ R     World J Gastroenterol    December 14, 2005   Volume 11   Number 46
be hypothesized that carriership of  the allele TLR9 -1237C 
(with or without CD14 -260T) is associated with an 
impaired immune response at the level of  the ileal tissue. 
Paneth cells are located in the crypts and are central in 
host defense to luminal bacteria by releasing antimicrobial 
substances[47,48].
    If  this is true, carriership of  allele TLR9 -1237C may 
become an important predictive marker to the enhanced 
risk of  developing refractory chronic pouchitis and 
eventually pouch failure. 
    SNPs in different genes might work synergistically and 
constitute a small to moderate relative risk of  developing 
diseases. Though the observations we described in this 
article were based on a relatively less number of  patients, 
it should be realized that this study might represent one of  
the largest series available.
    In conclusion, our data suggest that the alleles TLR9-
1237C and CD14-260T synergistically enhance the risk 
of  developing chronic relapsing pouchitis and eventually 
pouch failure in ulcerative colitis patients who need 
surgical intervention. Larger studies are required to 
determine whether this allelic combination becomes a 
valuable predictive marker and functional studies on the 
biological role of  TLR9 and CD14 in pouchitis.
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